Brain-targeting drug delivery systems: The state of the art in treatment of glioblastoma

作者：Bo Sun, Rong Li, Ning Ji, Han Liu, Hongxiang Wang, Chao Chen, Long Bai, Jiacan Su, Juxiang Chen · 发表于：Materials Today Bio · 年份：2025 · DOI：10.1016/j.mtbio.2025.101443 · 被引用次数：38 · 研究领域：RNA Interference and Gene Delivery、Extracellular vesicles in disease、MicroRNA in disease regulation

Glioblastoma (GBM) is the most prevalent primary malignant brain tumor, characterized by a high mortality rate and a poor prognosis. The blood-brain barrier (BBB) and the blood-tumor barrier (BTB) present significant obstacles to the efficacy of tumor-targeted pharmacotherapy, thereby impeding the therapeutic potential of numerous candidate drugs. Targeting delivery of adequate doses of drug across the BBB to treat GBM has become a prominent research area in recent years. This emphasis has driven the exploration and evaluation of diverse technologies for GBM pharmacotherapy, with some already undergoing clinical trials. This review provides a thorough overview of recent advancements and challenges in targeted drug delivery for GBM treatment. It specifically emphasizes systemic drug administration strategies to assess their potential and limitations in GBM treatment. Furthermore, this review highlights promising future research directions in the development of intelligent drug delivery systems aimed at overcoming current challenges and enhancing therapeutic efficacy against GBM. These advancements not only support foundational research on targeted drug delivery systems for GBM but also offer methodological approaches for future clinical applications. The prospects for designing drug delivery systems include advancing these systems to clinical applications for the treatment of GBM. • The strategies and applications of non-invasive systemic drug delivery technologies for the tre...